Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience

Blood Cancer J. 2023 May 31;13(1):91. doi: 10.1038/s41408-023-00859-x.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Humans
  • Multiple Myeloma* / drug therapy
  • POEMS Syndrome*
  • Thalidomide / therapeutic use

Substances

  • carfilzomib
  • daratumumab
  • pomalidomide
  • Thalidomide